14 Nov 2007 - Beactica AB announced that it has entered into a drug discovery collaboration agreement with Arrow Therapeutics Ltd (London, UK) whereby Beactica will direct its novel characterisation technology at selected Arrow compounds against a confidential target.
"We are very pleased to be working with Arrow" said Beactica's CEO, Dr Per Kallblad. "The company has a world-class reputation for conducting break through research in the antiviral field and we look forward to applying our technology on their targets."
CEO of Arrow Therapeutics, Dr Ken Powell, said "Working with Beactica provides us with an opportunity to apply a new technology that has already shown strong potential."
 |
www.bionity.com/news/e/74245 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/74245 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |